New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study.
Saved in:
| Title: | New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study. |
|---|---|
| Authors: | Tada, Toshifumi1,2 (AUTHOR) tadat0627@gmail.com, Kumada, Takashi3 (AUTHOR), Hiraoka, Atsushi4 (AUTHOR), Kariyama, Kazuya5 (AUTHOR), Tani, Joji6 (AUTHOR), Hirooka, Masashi7 (AUTHOR), Takaguchi, Koichi8 (AUTHOR), Atsukawa, Masanori9 (AUTHOR), Fukunishi, Shinya10 (AUTHOR), Itobayashi, Ei11 (AUTHOR), Tsuji, Kunihiko12 (AUTHOR), Tajiri, Kazuto13 (AUTHOR), Ochi, Hironori14 (AUTHOR), Ishikawa, Toru15 (AUTHOR), Yasuda, Satoshi16 (AUTHOR), Ogawa, Chikara17 (AUTHOR), Toyoda, Hidenori16 (AUTHOR), Hatanaka, Takeshi18 (AUTHOR), Nishimura, Takashi1 (AUTHOR), Kakizaki, Satoru19 (AUTHOR) |
| Source: | Cancer Medicine. Mar2023, Vol. 12 Issue 6, p6980-6993. 14p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
